Role of ELP6 in tumour progression and impact on ERK1/2 signalling pathway inhibitors in skin cutaneous melanoma

Elongator acetyltransferase complex subunit 6 (ELP6), a subunit of the elongator complex, can increase the migratory potential of melanoma cells in vitro. However, the clinical relevance of ELP6 in patients with melanoma remains unclear. The present study aimed to investigate the role of ELP6 expression in melanoma progression and association with patient survival rates. Transcriptomic data from patients with melanoma available in The Cancer Genome Atlas, Gene Expression Profiling Interactive Analysis and cBioPortal databases were analysed to evaluate the associations between ELP6 expression levels and patient survival. In vitro experiments were conducted using short hairpin RNAs to downregulate ELP6, with a focus on cell viability, cell cycle regulation and the ERK1/2 signalling pathway. ELP6 expression levels were significantly elevated in patients with melanoma and were associated with poor survival outcomes. Knockdown of ELP6 resulted in decreased expression levels of p42 MAPK, reduced cell viability, G1 phase cell cycle arrest and led to reduced responsiveness to the MEK1/2 inhibitor U0126. ELP6 promotes melanoma progression via the ERK1/2 signalling pathway. Therefore, assessing ELP6 expression may offer potential therapeutic strategies for patients with melanoma.

• Publication year

  2025

• Venue

  Oncology Letters

• Publication date

  2025-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/ol.2025.14996PMID 40177137PMCID 11962575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Photo-neuro-immuno-endocrinology: How the ultraviolet radiation regulates the body, brain, and immune system

  2024influential reference
• Biosensors for melanoma skin cancer diagnostics.

  2024cited by this paper
• Hyaluronic Acid/Ellagic Acid as Materials for Potential Medical Application

  2024cited by this paper
• New panel of biomarkers to discriminate between amelanotic and melanotic metastatic melanoma

  2023cited by this paper
• Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors

  2023cited by this paper
• The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells

  2023cited by this paper
• How cancer hijacks the body's homeostasis through the neuroendocrine system.

  2023cited by this paper
• BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences

  2022cited by this paper
• Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship

  2022cited by this paper
• Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy

  2021cited by this paper
• Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036.

  2021cited by this paper
• Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling

  2021cited by this paper
• Trends in Incidence and Mortality of Skin Melanoma in Lithuania 1991–2015

  2021cited by this paper
• Germline Elongator mutations in Sonic Hedgehog medulloblastoma

  2020cited by this paper
• Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non–Small Cell Lung Cancer Survival

  2020cited by this paper
• Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5

  2020cited by this paper
• ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells

  2020cited by this paper
• Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

  2019cited by this paper
• Melanoma

  2018cited by this paper
• Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Colorectal cancer statistics, 2017

  2017cited by this paper
• GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

  2017cited by this paper
• HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution.

  2015cited by this paper
• Optimization of Codon Translation Rates via tRNA Modifications Maintains Proteome Integrity

  2015cited by this paper
• Lentiviral Vectors Mediate Long-Term and High Efficiency Transgene Expression in HEK 293T cells

  2015cited by this paper
• The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

  2014cited by this paper
• pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels

  2014influential reference
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

  2013cited by this paper
• Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma.

  2013cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• DERP6 (ELP5) and C3ORF75 (ELP6) Regulate Tumorigenicity and Migration of Melanoma Cells as Subunits of Elongator*

  2012cited by this paper
• The Elongator subcomplex Elp456 is a hexameric RecA-like ATPase

  2012influential reference
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012influential reference
• The role of BRAF V600 mutation in melanoma

  2012cited by this paper
• Ultraviolet B radiation differentially modifies catechol‐O‐methyltransferase activity in keratinocytes and melanoma cells

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.

  2009cited by this paper
• Melanoma

  2006cited by this paper
• Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation.

  2005cited by this paper
• Specific Inhibition of the Synthesis of Human Lysyl-tRNA Synthetase Results in Decreases in tRNALys Incorporation, tRNA3LysAnnealing to Viral RNA, and Viral Infectivity in Human Immunodeficiency Virus Type 1

  2003influential reference
• Elongator is a histone H3 and H4 acetyltransferase important for normal histone acetylation levels in vivo

  2002influential reference
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• The Ki‐67 protein: From the known and the unknown

  2000influential reference
• Nuclear translocation of mitogen‐activated protein kinase p42MAPK during the ongoing cell cycle

  1999cited by this paper
• A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme.

  1999influential reference
• PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.

  1999cited by this paper
• Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation.

  1999cited by this paper
• Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma

  1994influential reference
• Cancer statistics

  1989cited by this paper

• No citing papers are available for this paper.